Dynacure Revenue and Competitors
Estimated Revenue & Valuation
- Dynacure's estimated annual revenue is currently $930k per year.
- Dynacure's estimated revenue per employee is $77,500
Employee Data
- Dynacure has 12 Employees.
- Dynacure grew their employee count by -64% last year.
Dynacure's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Scientific Officer | Reveal Email/Phone |
Dynacure Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.6M | 81 | -5% | N/A | N/A |
#2 | $19.5M | 126 | -2% | N/A | N/A |
#3 | $36.3M | 234 | 22% | N/A | N/A |
#4 | $19.7M | 127 | -17% | N/A | N/A |
#5 | $14.3M | 92 | 0% | $179.5M | N/A |
#6 | $49.4M | 208 | -8% | €201.1M | N/A |
#7 | $44.5M | 287 | -3% | N/A | N/A |
#8 | $7.6M | 49 | N/A | N/A | N/A |
#9 | $6.4M | 41 | N/A | N/A | N/A |
#10 | $17.2M | 111 | -15% | N/A | N/A |
What Is Dynacure?
Dynacure is a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Dynacure is developing DYN101, an investigational antisense product candidate designed to reduce the expression of dynamin 2 protein for the treatment of Myotubular and Centronuclear Myopathies, in strategic collaboration with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders, including its DYN201 program for the treatment of Hereditary Spastic Paraplegias. Dynacure is headquartered in Strasbourg, France with a corporate office in Philadelphia, PA, USA.
keywords:N/A
N/A
Total Funding
12
Number of Employees
$930k
Revenue (est)
-64%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Dynacure News
STRASBOURG, France and PHILADELPHIA, June 9, 2021 /PRNewswire/ -- Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced today that the US Food and Dr ...
STRASBOURG, France and PHILADELPHIA, Feb. 26, 2021 /PRNewswire/ -- Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, today announced its recognition of Rar ...
STRASBOURG, France and PHILADELPHIA, Jan. 26, 2021 /PRNewswire/ -- Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced today that the U.S. Patent a ...
Other Companies in Illkirch-Graffenstaden
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $66.4M | 171 | 8% | N/A |
#2 | $54.4M | 218 | -6% | N/A |
#3 | $45M | 224 | 2% | N/A |
#4 | $39.7M | 256 | 5% | N/A |
#5 | $45.9M | 296 | 2% | N/A |